THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED
STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
OTTAWA, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation
company with a series of patent protected products that support and optimize human and animal health, announces that it has
received approval by the TSX Venture Exchange to extend the expiry date of outstanding warrants exercisable to purchase 1,163,738
common shares at $1.00 per share. Such warrants were issued by Avivagen on December 16, 2014 by way of a private placement and had
been set to expire on January 31, 2019. The Company has also received approval to extend the expiry date of a second tranche of
outstanding warrants exercisable to purchase 2,774,991 common shares at $0.90 per share. These warrants were issued by Avivagen on
June 1, 2016 by way of a private placement and had also been set to expire on January 31, 2019. The new expiry date for both sets
of warrants is October 30, 2019. All other terms and conditions of the warrants remain unchanged. The Company’s intention to seek
extension of these warrants was previously announced on December 20, 2018.
About Avivagen
Avivagen Inc. is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is
headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown,
Prince Edward Island. For more information, visit www.avivagen.com.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology arises from Avivagen’s discoveries about carotenoids, compounds that give
certain fruits and vegetables their bright colors. Specifically, Avivagen has discovered the naturally occurring compound that is
the actual source of ?-carotene’s non-vitamin A activity and uses the synthetic version of the compound as the source of activity
of Avivagen’s OxC-beta™ products. Importantly, the OxC-beta™ compound is a non-antibiotic means of maintaining optimal health and
growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added
to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan, Thailand & New
Zealand.
About Vivamune™ Health Chews (Vivamune)
Vivamune is an all-in-one chew that can dramatically simplify a pet’s supplement routine. Featuring a
newly-discovered, novel immune-supporting active ingredient, OxC-beta™, Vivamune targets joints, skin and digestive health all in a
single, tasty chew a pet will love. Vivamune is available for sale in the United States, Canada, Thailand & Taiwan. For more
information, visit www.vivamunehealth.com.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current
expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen
Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical
facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”,
“consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”,
“pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements about OxC-beta’s ability to fulfill the
global mandate to remove in-feed antibiotics as growth promoters are forward looking statements. These forward-looking statements
are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current
expectations. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the
reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com
Kym Anthony
Chairman & Interim CEO
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164
Website: www.avivagen.com
Copyright © 2019 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
![email logo (003).png](https://resource.globenewswire.com/media/36d34616-cf91-499e-8119-1b4c5fbee0ab/small/email-logo-003-png.png)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2NDAjNzQ3OTQ5OQ==)